Screener
Cytokinetics CYTK CapEx
CapEx at other companies
Other financials
Where this comes from
Reported directly by Cytokinetics in its filing.
Tagged under the XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.
The source filing: Cytokinetics’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 4:30 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-338217
| Line item | Six Months Ended / June 30, 2026 | Six Months Ended / June 30, 2025 |
|---|---|---|
| Investment in non-marketable equity security | — | (5,000) |
| Maturities of investments | 482,539 | 549,725 |
| Sales of investments | — | 5,992 |
| Purchases of property and equipment | (10,264) | (9,809) |
| Net cash (used in) provided by investing activities | (361,506) | 158,837 |
| Cash flows from financing activities: | ||
| Repayment of finance lease liabilities | — | (204) |
| Repayment of term loans | (6,329) | (5,378) |
ITEM 1. FINANCIAL STATEMENTS
FAQ
- What is Cytokinetics's capex?
- Cytokinetics (CYTK) reported capex of $4.33M in Q2 2026.
- How has Cytokinetics's capex changed year-over-year?
- Cytokinetics's capex increased by 4.6% year-over-year, from $4.15M to $4.33M.
- What is the long-term trend for Cytokinetics's capex?
- Over 4 years (2021 to 2025), Cytokinetics's capex has grown at a -15.6% compound annual growth rate (CAGR), from $48.87M to $24.81M.
- What does capex mean?
- Cash spent on property, plant, and equipment — the primary measure of investment in productive capacity and infrastructure.
Ask your AI about Cytokinetics's capex.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude